AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00660036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: On Days 1-3 of an inpatient hospital stay: 10 mg/m\^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
Study NCT00660036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: On Days 1-5 of an inpatient hospital stay: 100 mg/m\^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
Study NCT04864652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHILLS Procedure
Description: CHILLS Cryotherapy procedure
Study NCT04564391 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo supplement
Description: Placebo supplement, daily intake of placebo, 3 weeks of intervention; blinded to patients
Study NCT00151060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Study NCT00151060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00151060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01002859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sandimmum
Description: Intravenous injection of cyclosporine
Study NCT01002859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Injection of NaCl solution
Study NCT04748224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: a local anesthetic drug
Study NCT04748224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine plus dexmedetomidine
Description: bupivacaine is a local anesthetic drug plus dexmedetomidine is a new generation highly selective α2-adrenergic receptor (α2-AR) agonist that is associated with sedative and analgesic sparing effects
Study NCT03213626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 MG
Description: To be taken orally once daily
Study NCT03213626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib 100Mg Tab
Description: To be taken orally once daily
Study NCT03828084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine
Study NCT03828084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Combination drugs containing decitabine and tetrahydrouridine
Study NCT03333057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: Perfluorohexyloctane
Study NCT03333057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9% sodium chloride solution)
Study NCT03703375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine
Study NCT03703375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Romidepsin
Description: Romidepsin
Study NCT03703375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine
Study NCT02368340 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function testing performed
Study NCT02368340 — intervention group
Intervention type: OTHER
Intervention: Chest CT
Description: Chest CT scan to evaluate for pulmonary fibrosis
Study NCT02368340 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: Blood and urine sample collections
Study NCT03791437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital chest drainage system
Description: patients who received Digital chest drainage system
Study NCT03791437 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Not use Digital chest drainage system
Description: patients who not received Digital chest drainage system( traditional drainage system)
Study NCT02801162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional ABG analyser
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
Study NCT02801162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional ABG analyser
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
Study NCT02801162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proxima 3®
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
Study NCT02801162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proxima 3®
Description: pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
Study NCT05248087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The bonded McNamara-type appliance
Description: The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.
Study NCT05248087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The removable palatal expansion appliance
Description: The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
Study NCT04186000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV vaccine
Description: The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
Study NCT02645656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Arm
Description: Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
Study NCT04860284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine tablets
Description: Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
Study NCT03208062 — intervention group
Intervention type: OTHER
Intervention: collection of waste materials
Description: osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
Study NCT03114020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Inhalation Solution
Description: twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
Study NCT00853333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Study NCT00853333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Study NCT00853333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT03114020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Solution
Description: Twice a day 3 ml of placebo inhalation solution
Study NCT02942290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.
Study NCT02942290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study NCT00848042 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuroLase Therapy
Description: Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
Study NCT02485821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Study NCT02485821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02485821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT02485821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT02540837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Obturator nerve block
Study NCT02540837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Obturator nerve block with saline(placebo)
Study NCT03765996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decongestive Physiotherapy
Description: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
Study NCT03765996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decongestive Physiotherapy plus taping
Description: This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
Study NCT03327090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).
Description: Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
Study NCT03327090 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).
Description: Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
Study NCT01048463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nutriall
Description: The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
Study NCT04787315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional intensive functional rehabilitation + Workstations
Description: Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation
Study NCT04787315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intensive functional rehabilitation
Description: Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: intravenous
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: intravenous
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: intravenous
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: intravenous
Study NCT00688740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous
Study NCT03735355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of fibrostenotic area
Study NCT03735355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TTS balloon dilation
Description: Dilation of a stricture using TTS balloon
Study NCT00209443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadodiamide Injection
Study NCT02673021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
Study NCT03372616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive left ventricular diastolic function assessment
Description: Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
Study NCT03372616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive aortic blood pressure measurement
Description: Aortic blood pressure will be measured with polyethylene catheter in aortic root.
Study NCT03372616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive left ventricular diastolic function assessment
Description: Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
Study NCT04094350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF with a seed-and-recruit model
Description: The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
Study NCT04454892 — intervention group
Intervention type: OTHER
Intervention: Amyotrophic lateral sclerosis
Description: AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
Study NCT03372616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive aortic blood pressure measurement
Description: Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
Study NCT00794430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3381
Description: 100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
Study NCT00794430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, bid, for 13 weeks
Study NCT01290991 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Augment Bone Graft
Description: Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
Study NCT02595515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Description: Procedure: chiropractic treatment.
Study NCT04094350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF targeting household and neighborhood contacts
Description: In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
Study NCT04094350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF targeting the older population using mobile screening units
Description: The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
Study NCT04094350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive case finding
Description: Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
Study NCT02595515 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visit without active treatment
Description: Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
Study NCT00856557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seminar and Practicum
Description: A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
Study NCT00120120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (CC-5013)
Description: Lenalidomide 2-5 mg capsules taken one time per day
Study NCT04577170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography
Description: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
Study NCT03673176 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
Study NCT00358878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: oral administration once daily
Study NCT00625365 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DEFINITY®
Description: DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
Study NCT04439838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043
Study NCT00358878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study NCT02929511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocating single-file system
Description: The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
Study NCT02929511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational single-file system.
Description: The device is moving in continuous rotational. It is a single-fie endodontic file.
Study NCT04439838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04716166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometry
Description: 3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
Study NCT02929511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Protaper multi-file system
Study NCT00927667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received primary FVIII prophylaxis (started \< 2 years of age)